The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with...

  • Main
  • 2020 / 6
  • The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with...
Leukemia 2020 / 6

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., La Rosée, P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Leukemia
DOI:
10.1038/s41375-020-0891-0
Date:
June, 2020
File:
PDF, 798 KB
2020
Conversion to is in progress
Conversion to is failed